METHOD

A piggyBac-based toolkit for inducible genome editing in mammalian cells

MEGAN D. SCHERTZER,^{1,2} ELIZA THULSON,^{2,3} KEEAN C.A. BRACEROS,^{1,4} DAVID M. LEE,^{1,2} EMMA R. HINKLE,^{2,3} RYAN M. MURPHY,^{1,4} SUSAN O. KIM,^{1,8} EVA C.M. VITUCCI,^{5,6} and J. MAURO CALABRESE^{1,7}

¹Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599, USA

²Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, North Carolina 27599, USA

³Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA

⁴Curriculum in Mechanistic, Interdisciplinary Studies of Biological Systems, University of North Carolina, Chapel Hill, North Carolina 27599, USA

⁵Curriculum in Toxicology, University of North Carolina, Chapel Hill, North Carolina 27599, USA

⁶U.S. Environmental Protection Agency, University of North Carolina, Chapel Hill, North Carolina 27599, USA

⁷Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA

ABSTRACT

We describe the development and application of a novel series of vectors that facilitate CRISPR-Cas9-mediated genome editing in mammalian cells, which we call CRISPR-Bac. CRISPR-Bac leverages the piggyBac transposon to randomly insert CRISPR-Cas9 components into mammalian genomes. In CRISPR-Bac, a single piggyBac cargo vector containing a doxycycline-inducible Cas9 or catalytically dead Cas9 (dCas9) variant and a gene conferring resistance to Hygromycin B is cotransfected with a plasmid expressing the piggyBac transposase. A second cargo vector, expressing a single-guide RNA (sgRNA) of interest, the reverse-tetracycline TransActivator (rtTA), and a gene conferring resistance to G418, is also cotransfected. Subsequent selection on Hygromycin B and G418 generates polyclonal cell populations that stably express Cas9, rtTA, and the sgRNA(s) of interest. We show that CRISPR-Bac can be used to knock down proteins of interest, to create targeted genetic deletions with high efficiency, and to activate or repress transcription of protein-coding genes and an imprinted long noncoding RNA. The ratio of sgRNA-to-Cas9-to-transposase can be adjusted in transfections to alter the average number of cargo insertions into the genome. sgRNAs targeting multiple genes can be inserted in a single transfection. CRISPR-Bac is a versatile platform for genome editing that simplifies the generation of mammalian cells that stably express the CRISPR-Cas9 machinery.

Keywords: CRISPR; piggyBac; genome editing; stem cells; regulatory element; lncRNA

INTRODUCTION

Within the last decade, the CRISPR (clustered regularly interspaced short palindromic repeat) bacterial immune system has provided researchers with multiple new methods to control gene expression in mammalian genomes. Coexpression of the Cas9 (CRISPR-associated protein 9) nuclease from *Streptococcus pyogenes* along with an engineered single guide RNA (sgRNA) that targets a protein-coding exon is an effective way to introduce frameshift mutations in proteins of interest, owing to the fact that repair of the DNA break introduced by Cas9

often results in small deletions surrounding the cut site. Coexpression of Cas9 and multiple sgRNAs can also be used to excise larger regions from genes of interest, or to excise DNA regulatory elements (Ran et al. 2013; Canver et al. 2014; Aparicio-Prat et al. 2015; Zhu et al. 2016; Gasperini et al. 2017). Expression of a catalytically dead Cas9 (dCas9) fused to a transcriptional activation or repression domain can be used to up- or down-regulate gene expression when sgRNAs are targeted to promoters or regulatory elements of interest (Hsu et al. 2014; Wright et al. 2016).

⁸**Present address:** National Institute for Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA

Corresponding author: jmcablabr@med.unc.edu

Article is online at <http://www.rnajournal.org/cgi/doi/10.1261/rna.068932.118>.

© 2019 Schertzer et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Owing to the broad utility of CRISPR, multiple methods have been developed to deliver the CRISPR-Cas9 machinery to mammalian cells. Transient transfection of Cas9- and sgRNA-expressing plasmids, or of Cas9 protein and in vitro synthesized sgRNAs, are useful when the efficiency of transfection for the cell type of interest is high and when the desired endpoint can be reached via transient expression of Cas9 and the sgRNA. Lentiviral delivery of Cas9/sgRNA vectors is also possible, and provides distinct advantages when transfection efficiency is low, or when the desired endpoint requires stable expression and or integration of Cas9/sgRNAs into the genome, such as for studies performed in vivo or for genome-wide phenotypic screens (Hartenian and Doench 2015; Joung et al. 2017). However, delivery of the CRISPR machinery via lentivirus requires additional hands-on time, expertise, safety precautions, and cost relative to delivery via transient transfection.

The piggyBac transposon is a broadly used tool that allows DNA cargos up to 100 kilobases in length to be inserted into "AATT" sequences that are preferentially located in euchromatic regions of mammalian genomes (Ding et al. 2005; Cadinaños and Bradley 2007; Wilson et al. 2007; Wang et al. 2008; Li et al. 2011). Owing to its high efficiency of transposition, piggyBac has been used in a wide range of applications, including in the stable expression of multisubunit protein complexes, in the generation of transgenic mice and induced pluripotent stem cells, and in the large-scale production of recombinant proteins (Ding et al. 2005; Kaji et al. 2009; Yusa et al. 2009; Kahlig et al. 2010; Li et al. 2013). Most recently, piggyBac has begun to be used for CRISPR-based applications; piggyBac vectors have been used to study CRISPR off-target effects (Wu et al. 2014), to engineer mutations in human induced pluripotent stem cells (Wang et al. 2017), and to perform multiplexed activation of protein-coding and noncoding genes (Li et al. 2017).

Herein, we describe the creation and validation of a piggyBac-based system for inducible editing of mammalian genomes by CRISPR-Cas9. In the system, which we call "CRISPR-Bac," two separate piggyBac cargo vectors, one that expresses an inducible Cas9 or dCas9 variant, and another that expresses an sgRNA and the reverse-tetracycline transactivator (rtTA; Gossen et al. 1995), are transfected into cells along with a plasmid that expresses the piggyBac transposase. A short period of selection is used to obtain cells that stably express both the Cas9 and sgRNA cargo vectors. Our CRISPR-Bac vectors provide a simple way to rapidly insert the CRISPR-Cas9 machinery into mammalian genomes to knock down proteins, delete kilobase-sized genomic regions, and activate or repress transcription of protein-coding genes and long noncoding RNAs (lncRNAs), without the additional cost and labor involved in the packaging and delivery of lentiviral particles to cells.

RESULTS

Cloning of CRISPR-Bac

We modeled CRISPR-Bac (Fig. 1) after the pX330 plasmid system in which a humanized version of the Cas9 enzyme from *Streptococcus pyogenes* is coexpressed with a chimeric sgRNA driven by a U6 promoter (Cong et al. 2013). We cloned the Cas9 from pX330 into a doxycycline-inducible expression cassette in a piggyBac cargo vector that also expresses a gene conferring resistance to Hygromycin B. We then converted the dual BbsI sites in pX330, which are used to clone the sgRNA targeting sequence into that vector, into dual BsmI sites. Like BbsI, BsmI is a Type IIS restriction enzyme, and it generates overhanging ends that are identical to those generated by BbsI. We cloned the BsmI-modified sgRNA expression cassette into a piggyBac cargo from Kirk et al. (2018) that expresses a bicistronic message which encodes the rtTA3 gene and a gene conferring resistance to G418 (originally cloned from Addgene plasmid #25735; Shin et al. 2006). The conversion of the pX330 BbsI sites, which are not unique in the rtTA-expressing vector, to BsmI sites, allows the exact sgRNA design and cloning protocol for pX330 (Cong et al. 2013) to be used to clone sgRNAs into CRISPR-Bac.

Knockdown of a protein-coding gene using CRISPR-Bac

We tested whether CRISPR-Bac could be used to knock down a protein of interest in mouse embryonic stem cells (ESCs). We designed three sgRNAs targeting different exons of the *Ezh2* gene (Supplemental Fig. S1; Supplemental Table S1) and cloned them into our sgRNA-rtTA-expressing vector using the protocol outlined in Cong et al. (2013). We then cotransfected our inducible Cas9-expressing piggyBac vector, a plasmid expressing the piggyBac transposase, and either each sgRNA-expressing vector separately, or a pool of all three sgRNAs into ESCs. As a control, we transfected an sgRNA-rtTA-expressing vector into which we did not clone a specific sgRNA-targeting sequence (our "no sgRNA" control). After selecting ESCs on Hygromycin B and G418 for 10 d, we removed the selection drugs and added 1 μ g/mL of doxycycline to the media for 4 d to induce the expression of Cas9. To assess the extent of EZH2 knockdown, we performed western blot and immunofluorescence (IF). Relative to the control ESCs, we observed >60% reduction in EZH2 protein levels in the three lines expressing individual sgRNAs and more than 90% loss in the line expressing the pool of sgRNAs (Fig. 2A). In repeat transfections of the sgRNA pool, we consistently observed >90% loss of EZH2 protein levels (Fig. 2B). IF to EZH2 confirmed our western blot analysis (Fig. 2C). We compared the levels of EZH2 knockdown obtained via CRISPR-Bac to those

obtained via transient transfection of the same sgRNA pool cloned into the widely used pX330 vector (Cong et al. 2013). Four days after transfection of pX330, we harvested cells and performed western blot and IF. Relative to pX330 lacking a gene-targeting sgRNA ("No sgRNA" control), we measured 25%–35% reduction in EZH2 protein (Fig. 2D,E). These results demonstrate that CRISPR-Bac can be used to inducibly knock down a protein-coding gene of interest.

Targeted deletion of genetic elements using CRISPR-Bac

An important use of CRISPR-Cas9 is to create targeted deletions of regulatory elements (Ran et al. 2013; Canver et al. 2014; Hsu et al. 2014; Aparicio-Prat et al. 2015; Wright et al. 2016; Zhu et al. 2016; Gasperini et al. 2017). To test the utility of CRISPR-Bac in this application, we cloned into CRISPR-Bac pairs of sgRNAs that flank multiple different regulatory elements (RE1, RE2, RE3, RE4), to delete 2331 bp, 2480 bp, 1222 bp, and 2609 bp regions, respectively (Supplemental Fig. S1; Supplemental Table S1). We created ESCs that stably express the different sgRNA pairs along with doxycycline-inducible Cas9. We induced expression of Cas9 for 4 d, collected genomic DNA, and performed quantitative PCR (qPCR) using amplicons within the deleted regions. By comparing qPCR results between the sgRNA-expressing ESCs and nontargeting sgRNA control ESCs, we approximated the extent that each targeted region was deleted in a polyclonal cell population. For four of four deletions, we observed more than 40% reduction in signal, indicating that close to half of the alleles in the cell population were deleted (Fig. 3A; two-sided *t*-test).

To assess deletion efficiency in single cells, we isolated 36 individual colonies from cells transfected with sgRNAs to the RE3 element and extracted their genomic DNA. To assess whether a deletion occurred on at least one allele, we performed PCR using primers that flanked the expected deletion. Twenty-one of 36 clones (58%) showed a band within the expected size range for a

FIGURE 1. Experimental pipeline used for CRISPR-Bac. In a CRISPR-Bac experiment, a Cas9-expressing piggyBac cargo vector (or dCas9 variant) is cotransfected with a sgRNA- and rTA-expressing piggyBac cargo vector and with a piggyBac transposase plasmid. Growth in Hygromycin B and G418 for 7 to 12 d selects for a population of cells that stably express an sgRNA of interest, and inducibly express a Cas9 or dCas9 variant. TR, piggyBac inverted terminal repeat. HS4, chicken β globin insulator element. TRE, tetracycline responsive element (i.e., doxycycline inducible promoter). hCas9, dCas9-VP160, dCas9-KRAB from Cheng et al. (2013), Cong et al. (2013), and Kearns et al. (2014). EF1, EF1 α promoter. HygroR, Hygromycin B resistance gene. SV40pA, SV40 polyadenylation signal. hU6-chimeric sgRNA from Cong et al. (2013) with BsmI sites replacing BbsI sites. hUbiC-rTA3-IRES-G418R cassette was from pSLIK-Neo (Shin et al. 2006).

deletion (310–426 bp; Fig. 3B), signifying that these clones were at least heterozygous for the deletion. To distinguish between clones that were heterozygous versus homozygous for the deletion, we used a pair of primers that amplify inside the deletion. Twelve out of the 21 clones (33% of the 36 clones) did not show a band, indicating that no wild-type allele was present, and the cells were homozygous for the deletion (Fig. 3C). Many homozygous clones showed weak wild-type bands, which we presume were due to genomic DNA from MEF feeder cells and not due to the presence of a wild-type allele in the clones. In support of this notion, we performed qPCR to detect the

FIGURE 2. Inducible protein-coding gene knockdown with CRISPR-Bac. See Supplemental Table S2 for details on replicates and experimental design for each figure panel. (A) Western blot of CRISPR-Bac assay in which three separate sgRNAs targeting *Ezh2*, a pool of all three sgRNAs, or a nontargeting sgRNA control ("No sgRNA") were cotransfected along with the inducible Cas9-expressing piggyBac cargo into E14 mouse ESCs. Western blots to EZH2 and TBP were performed on protein extracted from stably selected cells, after 4 d of Cas9 induction with doxycycline. Values underneath blots represent knockdown of EZH2 relative to no sgRNA controls and normalized for loading with TBP protein levels. (B) Biological replicates of experiment in A for sgRNA pool. "Pool rep #1" is the same sample as in A. (C) Representative IF image showing EZH2 knockdown in nontargeting sgRNA control ("no sgRNA") or pooled sgRNA cells from replicate #2 in B. Scale bar, 10 μ m. (D,E) Western blot and IF to EZH2 in transient transfection experiments with pX330.

wild-type allele on seven total clones: two clones classified as wild-type, two as heterozygous, and three as homozygous. Relative to heterozygous and wild-type clones, all three homozygous clones showed a 10 and 11 cycle difference, respectively, signifying that the clones that we genotyped as homozygous indeed lacked wild-type alleles (Fig. 3D). These data demonstrate that CRISPR-Bac can be used to generate targeted genomic deletions with high efficiency.

Activation and repression of protein-coding gene transcription using CRISPR-Bac

In addition to creating targeted genomic deletions, the CRISPR-Cas9 system can be used to up- or down-regulate genes from their endogenous promoters, by targeting dCas9 fused to effector domains that recruit transcriptional coactivators or corepressors. We cloned one such transcriptional activator fusion, dCas9-VP160 from Cheng et al. (2013), and one such transcriptional repressor

fusion, dCas9-KRAB from Kearns et al. (2014), into the same piggyBac-based inducible expression vector that we used to express catalytically active Cas9 (Fig. 1). We then tested our ability to up-regulate *Ascl1*, a silent gene in ESCs, with dCas9-VP160, and we tested our ability to down-regulate *Oct4*, an active gene in ESCs, with dCas9-KRAB (Fig. 4A). Using CRISPR-Bac, we routinely observed 350-fold up-regulation of *Ascl1* relative to nontargeting sgRNA control cells (Fig. 4B). This level of activation was similar to that obtained using transient transfection of dCas9-VP160 and SPgRNA vectors from Cheng et al. (2013) and Perez-Pinera et al. (2013) (Fig. 4B). Using multiple sets of published and in-house-designed sgRNAs, the maximum level of *Oct4* down-regulation we achieved was two- to threefold (Fig. 4C and data not shown). Relative to the 4 d used for protein knockdown and genomic deletions, we observed that for transcriptional modulation experiments, 2 d of doxycycline treatment was sufficient to detect maximal effects induced by dCas9-VP160 and -KRAB. These data show that CRISPR-Bac can be used to up- and down-regulate transcription of protein-coding genes of interest.

Activation and repression of lncRNA transcription using CRISPR-Bac

We next examined whether we could use CRISPR-Bac to activate and repress transcription of a lncRNA using dCas9-VP160 and dCas9-KRAB, respectively. We chose to target a lncRNA called *Airm* in two cell types: mouse ESCs, in which *Airm* is expressed at low levels, and mouse trophoblast stem cells (TSCs), in which *Airm* is more highly expressed and active (Fig. 5A; Latos et al. 2009; Calabrese et al. 2015; Andergassen et al. 2017). In ESCs, we were able to activate *Airm* ~15-fold above its levels in nontargeting sgRNA control cells (Fig. 5B), but we were not able to repress *Airm*, likely due to its low endogenous expression (data not shown; Latos et al. 2009). Compared to transient transfection of dCas9-VP160 and SPgRNA vectors from (Cheng et al. 2013; Perez-Pinera et al. 2013), we achieved a greater level of activation with CRISPR-Bac (Fig. 5B). In TSCs, we were able to repress *Airm* to 10% of its normal expression and activate *Airm* 2.5-fold relative to

RNA fluorescence in situ hybridization (FISH) in ESCs stably expressing dCas9-VP160 and either a nontargeting sgRNA or an *Airm*-targeting sgRNA. We performed a two-color RNA FISH experiment where one probe was complementary to the *Airm* lncRNA, and the other probe was complementary to the *Kcnq1ot1* lncRNA. *Kcnq1ot1*, like *Airm*, is also imprinted and monoallelically expressed (Lee and Bartolomei 2013). Unlike *Airm*, *Kcnq1ot1* is robustly expressed in ESCs under normal conditions (Umlauf et al. 2004). *Kcnq1ot1* therefore served as a control to gauge the extent of *Airm* monoallelism upon activation by CRISPR-Bac. After taking z-stacks on a widefield microscope and deconvolving the resultant images, we used an automated pipeline to identify puncta whose RNA FISH signal surpassed a specified threshold. In two images taken of cells expressing the nontargeting sgRNA control, we counted zero puncta of *Airm* relative to 100 puncta of *Kcnq1ot1*, confirming prior data that show *Kcnq1ot1* is robustly expressed in ESCs while *Airm* is not (Umlauf et al. 2004; Latos et al. 2009). In contrast, in two images taken of cells expressing the *Airm*-targeting sgRNA, we counted 97 puncta of *Airm* relative to 130 puncta of *Kcnq1ot1* (Fig. 5D). These data support the notion that CRISPR-Bac activates expression of *Airm* on the unmethylated paternal allele, and that the methylated maternal allele of *Airm* remains resistant to activation (Stoeger et al. 1993).

The number of piggyBac cargos inserted into the genome can be controlled by altering the ratio of cargo vector to transposase plasmid

(Cadinaños and Bradley 2007; Wilson et al. 2007; Wang et al. 2008). The CRISPR-Bac platform relies on simultaneous delivery of two cargo vectors: one vector expressing the sgRNA and *rtTA/G418* resistance genes, and the other vector expressing the Cas9/dCas9 variant and hygromycin resistance genes (Fig. 1). We sought to determine whether the extent of activation of a target gene of interest could be altered by altering the ratios of sgRNA, Cas9, and piggyBac transposase vectors in transfections. We tested a range of sgRNA-to-dCas9VP160-to-transposase ratios, using the *Airn* lncRNA as our target gene for activation (Supplemental Table S3). We found modest but significant differences in the level of *Airn* activation when we transfected higher amounts of sgRNA and dCas9-VP160 plasmids relative to the piggyBac transposase plasmid (Fig. 6A; see table of adjusted *P*-values from Tukey's HSD test), and these differences were accompanied by increased numbers of sgRNA and dCas9-VP160 cargo insertions per cell (Fig. 6B). Thus, the extent of target gene activation using CRISPR-Bac can be partly controlled by changing the ratios of sgRNA/*rtTA*, Cas9, and transposase plasmids in transfections.

Simultaneous up-regulation of two genes via CRISPR-Bac

By coexpression of multiple sgRNAs, CRISPR can be used to activate or repress multiple genes simultaneously (Cheng et al. 2013). To test if CRISPR-Bac is capable of multiplexed gene activation, we created ESCs expressing dCas9-VP160 and sgRNAs targeting the *Ascl1* and *Airn* promoters (same sgRNAs as in Figs. 4B, 5B,C, 6A). Relative to nontargeting sgRNA controls, qPCR demonstrated simultaneous 411-fold activation of *Ascl1* and 9.5-fold activation of *Airn* when sgRNAs for both targets were cotransfected (Fig. 6C). This confirms that CRISPR-Bac can be used to target multiple genes in a single experiment.

CRISPR-Bac can be used in human cells

To determine if the CRISPR-Bac system could be used in human cells, we tested Cas9-mediated knockdown and dCas9-VP160-mediated up-regulation in SUM-159 cells,

FIGURE 4. Activation and repression of protein-coding gene transcription using CRISPR-Bac. See Supplemental Table S2 for details on replicates and experimental design for each figure panel. Individual qPCR data points are shown in box-and-whisker format representing the mean and the interquartile range. (***) $P < 0.001$ from a two-sided *t*-test between no sgRNA and sgRNA-expressing cells. (A) qPCR results showing endogenous expression of *Ascl1* and *Oct4* in ESCs relative to the average *Ascl1* signal. (B) qPCR showing transcriptional activation of *Ascl1* using stable transfection of CRISPR-Bac dCas9-VP160 and a pool of four *Ascl1*-targeting sgRNAs (Perez-Pinera et al. 2013) versus transient transfection of dCas9-VP160 and pooled SPgRNA-*Ascl1*. Data from the nontargeting sgRNA control (No sgRNA) and sgRNA-expressing cells are plotted relative to the average of the signal in the No sgRNA control cells. (C) qPCR showing transcriptional repression of *Oct4* using dCas9-KRAB. Data are plotted as in B.

a commonly used cell line in breast cancer research (Grigoriadis et al. 2012). Similar to our experiments in ESCs, we cotransfected the inducible Cas9-expressing piggyBac vectors into SUM-159 cells, a plasmid expressing the piggyBac transposase, and a pool of four sgRNAs targeting human EZH2 exons, then selected the cells with Hygromycin B and G418 for at least 10 d, and induced Cas9 expression with 1 μ g/mL of doxycycline for 4 d. Via western blot, we detected >70% reduction in EZH2 protein levels in both replicates, which was confirmed via IF (Fig. 7A,B). In parallel, we cotransfected the dCas9-VP160, transposase, and a pool of two sgRNAs targeting the promoter of *Il1RN*, drug selected for at least 10 d, and induced dCas9-VP160 expression for 2 d. *Il1RN* was activated ~54-fold relative to the no dCas9 control (Fig. 7C). In these experiments, the Cas9/*EZH2* sgRNA cells served as a negative control in the dCas9-VP160/*Il1RN* sgRNA experiment, and vice versa. These data show that the CRISPR-Bac system can be used in human cells.

Conclusions

In *Mus musculus*-derived ESCs and TSCs, we have shown that CRISPR-Bac can be used to knock down proteins through frameshift/deletion, to delete kilobase-sized

FIGURE 5. Activation and repression of lncRNA transcription using CRISPR-Bac. See Supplemental Table S2 for details on replicates and experimental design for each figure panel. All individual qPCR data points are shown in box-and-whisker format representing the mean and the interquartile range. (***) $P < 0.001$; (**) $P < 0.01$ from a two-sided t -test between no sgRNA and sgRNA-expressing cells. (A) qPCR showing relative levels of *Aim* expression in wild-type ESCs and TSCs. (B) qPCR measuring *Aim* transcriptional activation in ESCs with stably transfected CRISPR-Bac constructs, dCas9-VP160 and *Aim*-targeting sgRNA, versus transient transfection of dCas9-VP160 and SPgRNA-*Aim*. Data from the nontargeting sgRNA control (No sgRNA) and sgRNA-expressing cells are plotted relative to the average of the signal in the No sgRNA control cells. (C) qPCR results for TSCs with stably transfected dCas9-KRAB or dCas9-VP160 and *Aim*-targeting sgRNA. Data are plotted as in B. (D) Representative RNA FISH image showing *Aim* and *Kcnq1ot1* RNA in ESCs harvested alongside ESCs from B. Numbers in parentheses correspond to spots counted by Imaris software for *Aim* and *Kcnq1ot1* in each cell line. Scale bar, 10 μ m.

regulatory elements with high efficiency, and to up- and down-regulate the transcription of protein-coding genes and an imprinted lncRNA. Levels of CRISPR-induced activation could partly be controlled through delivery of different ratios of CRISPR-Bac vectors. It seems likely that the use of different promoter elements within CRISPR-Bac (for example, a constitutive CMV promoter driving dCas9-VP160 instead of a TRE) might afford additional levels of control. It may also be possible to engineer CRISPR-Bac vectors that express multiple sgRNAs, as has been done elsewhere (Kabadi et al. 2014; Sakuma et al. 2014; Albers et al. 2015). Although in this work we only tested

CRISPR-Bac in a limited number of cell types, it seems reasonable to presume that the CRISPR-Bac vectors or their modified derivatives would be functional in other mammalian cell types, given the broad activity of the piggyBac transposase (Ding et al. 2005; Cadinaños and Bradley 2007; Wilson et al. 2007; Wang et al. 2008; Kaji et al. 2009; Yusa et al. 2009; Kahlig et al. 2010; Li et al. 2011, 2013). Indeed, CRISPR-Bac facilitated efficient knockdown and transcriptional up-regulation in at least one human cell line, SUM159 (Grigoriadis et al. 2012). In our view, the main utility of CRISPR-Bac over other genome editing platforms is that CRISPR-Bac allows the generation of stable cell lines without the need to package CRISPR-Cas9 components into lentiviral delivery systems. It also preserves the sgRNA cloning strategy from the widely used pX330/335 systems, facilitating horizontal transfer of sgRNAs between the two platforms (Cong et al. 2013). Relative to prior studies that have used piggyBac to carry out CRISPR in mammalian cells (Wu et al. 2014; Li et al. 2017; Wang et al. 2017), our study describes a single platform with interchangeable functionalities that has been optimized for protein knockdown, regulatory element deletion, and the up- and down-regulation of protein-coding and noncoding gene transcription.

MATERIALS AND METHODS

Construction of CRISPR-Bac vectors

To create the doxycycline-inducible Cas9, dCas9-VP160, and dCas9-KRAB piggyBac vectors, a parent piggyBac vector was created in which a bGH-polyA signal and an EF1 α promoter driving expression of a hygromycin resistance gene were ligated into the cumate-inducible piggyBac transposon vector from System Biosciences after its digestion with HpaI and SpeI, which cut just downstream from each chicken β -globin insulator sequence and removed all other internal components of the original vector. The TRE from pTRE-Tight (Clontech) was cloned upstream of the bGH-poly(A) site, and Cas9 from pX330 (Addgene plasmid # 42230; Cong et al. 2013; gift from Feng Zhang), dCas9-VP160 from Addgene plasmid # 48225 (Cheng et al. 2013; gift from Rudolf Jaenisch), and dCas9-KRAB from Addgene plasmid #

FIGURE 6. Cargo to transposase ratio controls the extent of activation and multiplex gene activation by CRISPR-Bac. See Supplemental Table S2 for details on replicates and experimental design for each figure panel. Each replicate in the no sgRNA control and sgRNA-expressing cells is shown relative to the average of the signal in "No sgRNA." (***) $P < 0.001$; (**) $P < 0.01$ from a two-sided t-test between no sgRNA and sgRNA-expressing cells. (A) qPCR measuring *Airm* activation. X-axis gives the transfection ratio of rtTA-sgRNA to dCas9-VP160 to transposase for each experiment. Ratios are plotted in ascending order based on the summed cargo (rtTA-sgRNA plus dCas9-VP160) to transposase ratio. "1:1:2 no sgRNA" and "8:2:1" data are the same as shown in Figure 5B. Corresponding table gives adjusted P -values from Tukey's HSD post-hoc test for all comparisons, where $P \leq 0.05$ are highlighted in green. (B) Bar plot showing DNA copy-number per cell for the rtTA-sgRNA and dCas9-VP160 cargos under each transfection condition. Numbers over each bar give the average copy-number calculated from three technical qPCR replicates. The tables below correspond to the bar plot showing the transfection ratio and total number of DNA cargos inserted (copy-number of rtTA-sgRNA plus dCas9-VP160). (C) Simultaneous activation of *Ascl1* and *Airm* transcription upon cotransfection of a pool of four *Ascl1* sgRNAs from Perez-Pinera et al. (2013) and one *Airm*. Data from the nontargeting sgRNA control (No sgRNA) and sgRNA-expressing cells are plotted relative to the average of the signal in the No sgRNA control cells. Individual qPCR data points are shown.

50917 (Kearns et al. 2014; gift from Rene Maehr and Scot Wolfe) were each cloned behind the TRE by digestion with *AgeI* and *Sall* (NEB) followed by Gibson Assembly (NEB), to generate piggyBac cargo vectors capable of inducibly expressing Cas9, dCas9-VP160, and dCas9-KRAB, respectively, upon addition of doxycycline.

To create the rtTA-sgRNA expressing piggyBac vector, the dual *BbsI* sites in pX330 were converted to *BsmBI* sites using oligonucleotides, and the entire U6 expression cassette was cloned via Gibson assembly into the *PacI* site upstream of the rtTA3-IRES-

Neo cassette in the rtTA-piggyBac-Cargo vector described in Kirk et al. (2018). The rtTA3-IRES-Neo cassette was originally cloned from pSLIK-Neo and was a gift from Iain Fraser (Addgene plasmid # 25735). Oligonucleotides used for cloning are in Supplemental Table S1.

We have submitted four plasmids to Addgene: (1) PB_rtTA_BsmBI, #126 028, (2) PB_tre_Cas9, #126029, (3) PB_tre_dCas9_KRAB, #126030, and (4) PB_tre_dCas9_VP160, #126031.

sgRNA design

Oligonucleotides used for sgRNA cloning are listed in Supplemental Table S1, and their location relative to gene features are shown in Supplemental Figure S1. Protein knockdown sgRNAs were designed using Desktop Genetics, and all other sgRNAs were designed using the CRISPOR program or taken from published sources (Supplemental Table S1; Haeussler et al. 2016).

Embryonic stem cell (ESC) culture

ESCs were grown on gelatin coated plates at 37°C in a humidified incubator at 5% CO₂. Media were changed daily and consisted of DMEM high glucose plus sodium pyruvate, 0.1 mM nonessential AA, 100 μ M penicillin-streptomycin, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 15% ES-qualified FBS, and 1:500 LIF conditioned media produced from Lif-1C α (COS) cells. ESCs were split at an approximate ratio of 1:6 every 48 h.

Trophoblast stem cell (TSC) culture

TSCs were cultured as in Quinn et al. (2006). Briefly, TSCs were cultured at 37°C on preplated irradiated MEF feeder cells in TSC media (RPMI [Invitrogen], 20% Qualified FBS [Invitrogen], 100 μ M penicillin-streptomycin, 1 mM sodium pyruvate [Invitrogen], 100 μ M β -mercaptoethanol [Sigma], and 2 mM L-glutamine) supplemented with Fgf4 (25 ng/mL; Invitrogen) and Heparin (1 μ g/mL; Sigma) just before use. At passage, TSCs were trypsinized with 0.125% Trypsin (Invitrogen) for 3 min at room temperature and gently dislodged from their plate with a sterile, cotton-plugged Pasteur pipette (Thermo Fisher). To deplete MEF feeder cells from TSCs prior to RNA isolation, TSCs were preplated for 40 min and cultured for 3 d in 70% MEF-conditioned TSC media supplemented with Fgf4 (25 ng/mL; Invitrogen) and Heparin (1 μ g/mL; Sigma).

FIGURE 7. The CRISPR-Bac system functions in human cell lines. See Supplemental Table S2 for details on replicates and experimental design for each figure panel. (A) Western blots to EZH2 and ERK2 loading control from two replicate CRISPR-Bac experiments in SUM-159 cells. “No Cas9” refers to measurements taken from dCas9-VP160/rtta-*IIRN* sgRNA expressing SUM-159 cells that were cultured in parallel to those expressing Cas9 and the *EZH2* sgRNA pool. Values underneath blots represent knockdown of EZH2 relative to No Cas9 control and normalized for loading with ERK2 protein levels. (B) Representative IF images showing EZH2 knockdown from “No Cas9” and “EZH2 pool, rep #1” SUM-159 cells in A. Image #1 shows a cell with partial knockdown next to a cell with full knockdown, and image #2 shows two cells with full knockdown. Scale bar, 10 μ m. (C) qPCR results showing transcriptional activation of *IIRN* in SUM-159 cells. In panel C, “No dCas9” refers to measurements taken from Cas9/rtta-*EZH2* sgRNA expressing SUM-159 cells that were cultured in parallel to those expressing dCas9 and the *IIRN* sgRNAs. Data from the nontargeting sgRNA control (No sgRNA) and sgRNA-expressing cells are plotted relative to the average of the signal in the No sgRNA control cells. Individual qPCR data points are shown in box-and-whisker format. (***) $P < 0.001$ from a two-sided t-test between no sgRNA and sgRNA-expressing cells.

SUM-159 cell culture

SUM-159 cells were maintained in DMEM/F12 medium (Gibco, Thermo Fisher Scientific) supplemented with 5% FBS, 5 μ g/mL insulin, 1 μ g/mL hydrocortisone, and antibiotic:antimycotic cocktail (Gemini Bio Products) as in Zawistowski et al. (2017).

Stable transfections of CRISPR-Bac components

To generate stable CRISPR-Bac E14 ESC lines, 5×10^5 cells were seeded in a single well of a six-well plate, and the next day transfected with piggyBac cargo vectors and pUC19-piggyBac

transposase from Kirk et al. (2018), totaling 2.5 μ g of plasmid DNA (see exact amounts in Supplemental Table S3), using Lipofectamine 3000 (Invitrogen) according to manufacturer instructions. Cells were subsequently selected on Hygromycin (150 μ g/mL; Gibco) and G418 (200 μ g/mL; Gibco) for 7 to 12 d. Due to the efficiency of piggyBac cargo integration and the rapidity of Hygromycin selection, most observable death from drug selection occurred within ~ 3 d after addition of Hygromycin and G418 (i.e., cells with Hygromycin resistance were invariably resistant to G418).

To generate stable CRISPR-Bac TSC lines, 7.5×10^5 cells were coelectroporated using the Neon instrument (electroporation program: 1300 V, 40 msec, 1 pulse; Invitrogen) with 5 μ g of plasmid DNA at a 1:1:2 ratio of rtTA-sgRNA to dCas9 to transposase. Cells were selected on Hygromycin (150 μ g/mL; Gibco) and G418 (200 μ g/mL; Gibco) for 9 d.

To generate stable CRISPR-Bac SUM-159 cells, 5×10^5 cells were seeded per well of a six-well plate and the next day transfected with 2.5 μ g of plasmid DNA at a 1:1:2 ratio of rtTA-sgRNA to Cas9 to transposase using Lipofectamine 3000 (Invitrogen). Cells were subsequently selected on Hygromycin (250 μ g/mL; Gibco) and G418 (600 μ g/mL; Gibco) for at least 10 d.

Transient transfections

For transient transfections using pX330, 5×10^5 ESCs were seeded in a single well of a six-well plate and transfected the next day using Lipofectamine 3000 with 2.5 μ g of the pX330 empty vector (“no sgRNA”) or a pool of pX330 vectors expressing the 3 sgRNAs to mouse *Ezh2*. Cells were harvested 4 d after transfection. For transient transfections using VP160, 5×10^5 ESCs were seeded in a single well of a six-well plate and transfected the next day using Lipofectamine 3000 with 1.25 μ g of dCas9-VP160 (Cheng et al. 2013) and 1.25 μ g of the SPgRNA empty vector (“no sgRNA”; Perez-Pinera et al. 2013) or SPgRNA containing sgRNAs targeting either *Aim* or *Ascl1*. Cells were harvested 2 d after transfection.

Protein isolation and western blotting

To isolate protein for western blotting, cells were washed with PBS, and then lysed with RIPA buffer (10 mM Tris-Cl (pH 7.5), 1 mM EDTA, 0.5 mM EGTA, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with 1 mM PMSF (Fisher Scientific) and 1 $\times$ protease inhibitor cocktail (Sigma) for 15 min at 4°C, 4 d after induction with 1 μ g/mL doxycycline. Prior to western blotting, protein levels were quantified using the DC assay from Bio-Rad. For western blotting, primary and secondary antibody incubations were done for 1 h at room temperature. Antibodies used were EZH2 (Cell Signaling #5246, 1:1000 dilution), TBP (Abcam ab818, 1:2000 dilution), ERK2 (Santa Cruz; sc-1647; 1:500), donkey anti-mouse IgG-HRP secondary (Santa Cruz; sc-2314; 1:2500), and donkey anti-rabbit IgG-HRP secondary (Santa Cruz; sc-2313; 1:2500).

Genomic DNA isolation and qPCR

To isolate genomic DNA, 400 μ L of ESC lysis buffer (100 mM Tris-HCl, pH 8.1, 5 mM EDTA, pH 8.0, 200 mM NaCl, 0.2% SDS)

supplemented with 80 μ L proteinase K (Denville) was used per 24-well of ESCs, four days after induction with 1 μ g/mL doxycycline. Lysed ESCs were incubated at 55°C overnight, cells were boiled at 100°C for 1 h to degrade RNA, and DNA was precipitated by addition of 2 volumes of 100% ethanol. DNA was pelleted and resuspended in 1 $\times$ TE (10 mM Tris-HCl 1 mM EDTA pH 8.0) overnight at room temperature prior to qPCR. qPCR was performed using 100 ng of DNA per reaction and iTaq Universal SYBR Green Supermix (Bio-Rad), with primers specified in Supplemental Table S1. All related plots were generated using R version 3.4.1 (The R Development Core Team 2017).

qPCR for DNA copy-number analysis

Genomic DNA was prepared as in Genomic DNA isolation and qPCR section above. qPCR signal (SsoFast, Bio-Rad) from the genomic DNA was compared to signal from a molar standard amplified from increasing amounts of the corresponding dCas9-VP160 and rtTA plasmids. Primers used are listed in Supplemental Table S1. All related plots were generated using R version 3.4.1 (The R Development Core Team 2017).

Generation of clonal ESCs with targeted genomic deletions and genotyping

After 4 d of dox induction, RE3 deletion E14 cells were cultured 2 d in the absence of dox to ensure that Cas9 was fully depleted. Then, 2000 cells were plated on a 10 cm plate with preplated irradiated MEF feeder cells. After 4 d, individual colonies were picked and plated on irMEFs. Clonal lines were passaged twice off of MEFs before genomic DNA was prepared as in Genomic DNA isolation and qPCR section above.

Genotyping PCR reactions were performed with gDNA using Apex Taq DNA Polymerase (Genesee Scientific). The first set of primers flanked the deletion and identified clonal lines with at least one allele deleted. The second set only amplified a wild-type allele, with both primers sitting inside the deletion. Many clones showed weak wild-type bands, likely due to MEF gDNA and not due to the presence of a wild-type allele in the ESC clone. Primers used are listed in Supplemental Table S1.

RNA isolation and qPCR

RNA was isolated using TRIzol (Invitrogen). For RT-qPCR assays, 1–2 μ g of RNA was reverse transcribed using MultiScribe RT (Applied Biosystems), and qPCR was performed using iTaq Universal SYBR Green (Bio-Rad) and primers specified in Supplemental Table S1. All related plots were generated using R version 3.4.1 (The R Development Core Team 2017).

RNA FISH

Fosmid WI1-2156F18 (*Airm*) and BAC RP23-101N20 (*Kcnq1ot1*) were ordered from the BACPAC resource center and fingerprinted with restriction digestion prior to use to verify inserted DNA. Fluorescent labeling was performed using BioPrime (Invitrogen). ESCs were fixed on coverslips for 10 min in 4% paraformaldehyde/PBS, followed by a 10-min permeabilization on ice in

0.5% TritonX-100 in PBS and 1:200 Ribonucleoside Vanadyl Complex (NEB). Coverslips were stored at –20°C in 70% ethanol until use.

To initiate the RNA FISH protocol, coverslips were dehydrated by serial 3-min incubations with 75%, 85%, 95%, and 100% ethanol, and air-dried for 5 min. RNA FISH probes were added, and coverslips were placed cell-side down in a chamber humidified with 50% formamide/2 $\times$ SSC overnight at 37°C. After overnight incubation, coverslips were washed 3 $\times$ with 50% formamide/2 $\times$ SSC at 42°C and 3 $\times$ with 1 $\times$ SSC at 50°C. Each wash was 5 min long. Coverslips were then rinsed 1 $\times$ with PBS before a 2 min incubation in DAPI stock diluted 1:1000 in water. Coverslips were rinsed twice more and affixed to glass slides using Vectashield (VectorLabs), then sealed with nail polish.

Four-dimensional data sets were acquired by taking multichannel Z-stacks on an Olympus BX61 widefield fluorescence microscope using a Plan-Aprochromat 60X/1.4 oil objective and a Hamamatsu ORCA R2 camera, controlled by Volocity 6.3 software. Excitation was provided by a mercury lamp, and the following filters were used for the three fluorescent channels that were imaged: 377/25 ex, 447/30 em for DAPI (DAPI-5060B Semrock filter); 482/17 ex, 536/20 em for AlexaFluor488 (Semrock FITC-3540B filter); 562/20 ex, 642/20 em for Cy3 (Semrock TXRED-4040B filter). Pixel size was 0.108 μ m, Z spacing was 0.2 μ m, and images had 1344 $\times$ 1024 pixels. Between 46–49 Z-stacks were acquired for each image. Z-stacks were deconvolved using the iterative-constrained algorithm (Mediacy AutoQuantX3) with default algorithm settings. Sample settings for the deconvolution were: peak emissions for dyes (570, 519, 461 nm for Cy3, AlexaFluor 488 and DAPI, respectively), widefield microscopy mode, NA = 1.4, RI of oil = 1.518, and RI of sample = 1.45. After deconvolution, RNA FISH signals were located using the “Spots” function in Imaris software (version 8.3.1) and marked with equal sized spheres. To initially call spots on all images, spot detection values were set at 0.5 μ m for xy and 1.5 μ m for z, and background subtraction and auto quality settings were used. We manually optimized the quality/sensitivity setting to call *Kcnq1ot1* spots, and then used the same quality threshold to call *Airm* spots for the same image. Images are shown as maximum intensity projections made using ImageJ (Schindelin et al. 2012).

Immunofluorescence (IF)

Cells were fixed on coverslips the same as for RNA FISH (see above). To initiate the IF protocol, coverslips were washed twice in PBS and blocked for 30 min at room temperature in blocking solution (1 $\times$ PBS with 0.2% Triton X-100, 1% goat serum, and 6 mg/mL IgG-free BSA). Then, coverslips were washed in 0.2% triton/1 $\times$ PBS and incubated with EZH2 antibody (Cell Signaling #5246; 1:200 in block solution) for 1 h at RT. Coverslips were washed 3 $\times$ in 0.2% triton/1 $\times$ PBS for 4 min each and incubated with secondary antibody (AlexaFluor 647 goat anti-rabbit, A-21245, 1:1000 in block solution for ESCs and AlexaFluor 488 goat anti-rabbit, A-11034, 1:1000 in block solution) for 30 min at RT. After incubation, coverslips were washed 3 $\times$ in 0.2% triton/1 $\times$ PBS for 4 min each and rinsed 1 $\times$ with PBS before a 2 min incubation in DAPI stock diluted to 5 ng/mL in water. Coverslips were rinsed twice more and mounted to glass slides using Prolong Gold (Thermo Fisher Scientific P10144). Imaging

and deconvolution were performed the same as described in the RNA FISH section with the below exceptions. The filters used for the two fluorescent channels that were imaged are 377/25 ex, 447/30 em for DAPI (DAPI-5060B Semrock filter), 482/17 ex, 536/20 em for AlexaFluor488, (Semrock FITC-3540B filter), and 628/20 ex, 692/20 em for AlexaFluor 647 (Semrock Cy5 4040A filter). Approximately 40 Z-stacks were acquired for each image. Sample settings for the deconvolution included the following peak emissions for dyes: 670, 519, and 461 nm for AlexaFluor 647, AlexaFluor 488, and DAPI, respectively. Images are shown as maximum intensity projections made using ImageJ (Schindelin et al. 2012).

SUPPLEMENTAL MATERIAL

Supplemental material is available for this article.

ACKNOWLEDGMENTS

We thank UNC colleagues for discussions and the Gary Johnson laboratory for the SUM-159 cell line. This work was supported by National Institutes of Health (NIH) grant GM121806, Basil O'Connor award #5100683 from the March of Dimes Foundation, and funds from the Lineberger Comprehensive Cancer Center and UNC Department of Pharmacology (to J.M.C.). E.T., D.M.L., and E.R.H. were supported in part by the National Institute of General Medical Sciences (NIGMS) training award T32 GM007092, K.C.A.B. and R.M.M. by the NIGMS training award T32 GM119999, and E.C.M.V. by the National Institute of Environmental Health Sciences (NIEHS) Toxicology Training grant T32 ES007126 and the NIGMS training award R25 GM055336. The Microscopy Services Laboratory was supported in part by National Cancer Institute (NCI) grant P30 CA016086.

Author contributions: M.D.S. and J.M.C. conceived the study; M.D.S., E.T., K.C.A.B., D.M.L., E.R.H., R.M.M., S.O.K., and E.C.M.V. performed the experiments; M.D.S. and J.M.C. performed the analysis; and M.D.S. and J.M.C. wrote the paper.

Received September 22, 2018; accepted May 15, 2019.

REFERENCES

- Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, Catalano A, Busenhardt P, Gonçalves AF, Brandt S, et al. 2015. A versatile modular vector system for rapid combinatorial mammalian genetics. *J Clin Invest* **125**: 1603–1619. doi:10.1172/JCI79743
- Andergassen D, Dotter CP, Wenzel D, Sigl V, Bammer PC, Muckenhuber M, Mayer D, Kulinski TM, Theussl HC, Penninger JM, et al. 2017. Mapping the mouse Allelome reveals tissue-specific regulation of allelic expression. *eLife* **6**: e25125. doi:10.7554/eLife.25125
- Aparicio-Prat E, Aman C, Sala I, Bosch N, Guigó R, Johnson R. 2015. DECKO: single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs. *BMC Genomics* **16**: 846. doi:10.1186/s12864-015-2086-z
- Cadinaños J, Bradley A. 2007. Generation of an inducible and optimized piggyBac transposon system. *Nucleic Acids Res* **35**: e87. doi:10.1093/nar/gkm446
- Calabrese JM, Starmer J, Schertzer MD, Yee D, Magnuson T. 2015. A survey of imprinted gene expression in mouse trophoblast stem cells. *G3 (Bethesda)* **5**: 751–759. doi:10.1534/g3.114.016238
- Canver MC, Bauer DE, Dass A, Yien YY, Chung J, Masuda T, Maeda T, Paw BH, Orkin SH. 2014. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. *J Biol Chem* **289**: 21312–21324. doi:10.1074/jbc.M114.564625
- Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB, Jaenisch R. 2013. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. *Cell Res* **23**: 1163–1171. doi:10.1038/cr.2013.122
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**: 819–823. doi:10.1126/science.1231143
- Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. 2005. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. *Cell* **122**: 473–483. doi:10.1016/j.cell.2005.07.013
- Gasparini M, Findlay GM, McKenna A, Milbank JH, Lee C, Zhang MD, Cusanovich DA, Shendure J. 2017. CRISPR/Cas9-mediated scanning for regulatory elements required for HPRT1 expression via thousands of large, programmed genomic deletions. *Am J Hum Genet* **101**: 192–205. doi:10.1016/j.ajhg.2017.06.010
- Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. 1995. Transcriptional activation by tetracyclines in mammalian cells. *Science* **268**: 1766–1769. doi:10.1126/science.7792603
- Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, Reis-Filho JS, Tutt A. 2012. Molecular characterisation of cell line models for triple-negative breast cancers. *BMC Genomics* **13**: 619. doi:10.1186/1471-2164-13-619
- Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud JB, Schneider-Maunoury S, Shkumatava A, Teboul L, Kent J, et al. 2016. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. *Genome Biol* **17**: 148. doi:10.1186/s13059-016-1012-2
- Hartenian E, Doench JG. 2015. Genetic screens and functional genomics using CRISPR/Cas9 technology. *FEBS J* **282**: 1383–1393. doi:10.1111/febs.13248
- Hsu PD, Lander ES, Zhang F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* **157**: 1262–1278. doi:10.1016/j.cell.2014.05.010
- Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F. 2017. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nat Protoc* **12**: 828–863. doi:10.1038/nprot.2017.016
- Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. 2014. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. *Nucleic Acids Res* **42**: e147. doi:10.1093/nar/gku749
- Kahlig KM, Saridey SK, Kaja A, Daniels MA, George AL Jr, Wilson MH. 2010. Multiplexed transposon-mediated stable gene transfer in human cells. *Proc Natl Acad Sci* **107**: 1343–1348. doi:10.1073/pnas.0910383107
- Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. 2009. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature* **458**: 771–775. doi:10.1038/nature07864
- Kearns NA, Genga RM, Enameh MS, Garber M, Wolfe SA, Maehr R. 2014. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. *Development* **141**: 219–223. doi:10.1242/dev.103341
- Kirk JM, Kim SO, Inoue K, Smola MJ, Lee DM, Schertzer MD, Wooten JS, Baker AR, Sprague D, Collins DW, et al. 2018.

- Functional classification of long non-coding RNAs by k-mer content. *Nat Genet* **50**: 1474–1482. doi:10.1038/s41588-018-0207-8
- Latos PA, Stricker SH, Steenpass L, Pauler FM, Huang R, Senergin BH, Regha K, Koerner MV, Warczok KE, Unger C, et al. 2009. An in vitro ES cell imprinting model shows that imprinted expression of the *Igf2r* gene arises from an allele-specific expression bias. *Development* **136**: 437–448. doi:10.1242/dev.032060
- Lee JT, Bartolomei MS. 2013. X-inactivation, imprinting, and long noncoding RNAs in health and disease. *Cell* **152**: 1308–1323. doi:10.1016/j.cell.2013.02.016
- Li MA, Turner DJ, Ning Z, Yusa K, Liang Q, Eckert S, Rad L, Fitzgerald TW, Craig NL, Bradley A. 2011. Mobilization of giant piggyBac transposons in the mouse genome. *Nucleic Acids Res* **39**: e148. doi:10.1093/nar/gkr764
- Li Z, Michael IP, Zhou D, Nagy A, Rini JM. 2013. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. *Proc Natl Acad Sci* **110**: 5004–5009. doi:10.1073/pnas.1218620110
- Li S, Zhang A, Xue H, Li D, Liu Y. 2017. One-step piggyBac transposon-based CRISPR/Cas9 activation of multiple genes. *Mol Ther Nucleic Acids* **8**: 64–76. doi:10.1016/j.omtn.2017.06.007
- Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, et al. 2013. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat Methods* **10**: 973–976. doi:10.1038/nmeth.2600
- Quinn J, Kunath T, Rossant J. 2006. Mouse trophoblast stem cells. *Methods Mol Med* **121**: 125–148. doi:10.1385/1-59259-983-4:123
- The R Development Core Team. 2017. *R: a language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. <https://www.r-project.org>.
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**: 2281–2308. doi:10.1038/nprot.2013.143
- Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T. 2014. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. *Sci Rep* **4**: 5400. doi:10.1038/srep05400
- Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**: 676–682. doi:10.1038/nmeth.2019
- Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI, Rebres R, Roach T, Seaman W, Simon MI, et al. 2006. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. *Proc Natl Acad Sci* **103**: 13759–13764. doi:10.1073/pnas.0606179103
- Stoger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H, Barlow DP. 1993. Maternal-specific methylation of the imprinted mouse *Igf2r* locus identifies the expressed locus as carrying the imprinting signal. *Cell* **73**: 61–71. doi:10.1016/0092-8674(93)90160-R
- Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, Zhang Y, Feil R. 2004. Imprinting along the *Kcnq1* domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. *Nat Genet* **36**: 1296–1300. doi:10.1038/ng1467
- Wang W, Lin C, Lu D, Ning Z, Cox T, Melvin D, Wang X, Bradley A, Liu P. 2008. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. *Proc Natl Acad Sci* **105**: 9290–9295. doi:10.1073/pnas.0801017105
- Wang G, Yang L, Grishin D, Rios X, Ye LY, Hu Y, Li K, Zhang D, Church GM, Pu WT. 2017. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies. *Nat Protoc* **12**: 88–103. doi:10.1038/nprot.2016.152
- Wilson MH, Coates CJ, George AL Jr. 2007. PiggyBac transposon-mediated gene transfer in human cells. *Mol Ther* **15**: 139–145. doi:10.1038/sj.mt.6300028
- Wright AV, Nuñez JK, Doudna JA. 2016. Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering. *Cell* **164**: 29–44. doi:10.1016/j.cell.2015.12.035
- Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, Cheng AW, Trevino AE, Konermann S, Chen S, et al. 2014. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. *Nat Biotechnol* **32**: 670–676. doi:10.1038/nbt.2889
- Yusa K, Rad R, Takeda J, Bradley A. 2009. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. *Nat Methods* **6**: 363–369. doi:10.1038/nmeth.1323
- Zawistowski JS, Bevil SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, et al. 2017. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. *Cancer Discov* **7**: 302–321. doi:10.1158/2159-8290.CD-16-0653
- Zhu S, Li W, Liu J, Chen CH, Liao Q, Xu P, Xu H, Xiao T, Cao Z, Peng J, et al. 2016. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. *Nat Biotechnol* **34**: 1279–1286. doi:10.1038/nbt.3715

RNA

A PUBLICATION OF THE RNA SOCIETY

A piggyBac-based toolkit for inducible genome editing in mammalian cells

Megan D. Schertzer, Eliza Thulson, Kean C.A. Bracer, et al.

RNA 2019 25: 1047-1058 originally published online May 17, 2019

Access the most recent version at doi:[10.1261/rna.068932.118](https://doi.org/10.1261/rna.068932.118)

Supplemental Material

<http://rnajournal.cshlp.org/content/suppl/2019/05/17/rna.068932.118.DC1>

References

This article cites 42 articles, 11 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/25/8/1047.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:

<http://rnajournal.cshlp.org/subscriptions>